Atrys Health, S.A. (BME:ATRY)

Spain flag Spain · Delayed Price · Currency is EUR
2.855
-0.070 (-2.39%)
Apr 28, 2026, 5:35 PM CET
0.18%
Market Cap 222.03M
Revenue (ttm) 144.31M
Net Income (ttm) -100.30M
Shares Out 75.91M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE 50.59
Dividend n/a
Ex-Dividend Date n/a
Volume 30,598
Average Volume 89,861
Open 2.960
Previous Close 2.925
Day's Range 2.850 - 2.960
52-Week Range 2.480 - 3.590
Beta 0.56
RSI 46.54
Earnings Date Jun 22, 2026

About Atrys Health

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 1,985
Stock Exchange Madrid Stock Exchange
Ticker Symbol ATRY
Full Company Profile

Financial Performance

In 2025, Atrys Health's revenue was 144.31 million, an increase of 7.00% compared to the previous year's 134.88 million. Losses were -100.30 million, 215.7% more than in 2024.

Financial Statements

News

Atrys Health Earnings Call Transcript: Q2 2024

Revenue grew 5% to €107.4M and adjusted EBITDA rose 24.6% to €25.2M, driven by operational efficiencies and strong growth in oncology and prevention. Guidance for 2024 is reaffirmed, with net profit expected to break even in 2025.

1 year ago - Transcripts